While research has accelerated the development of new treatments for pediatric neurodegenerative 20 disorders, the ability to demonstrate the long-term efficacy of these therapies has been hindered by the lack of 21 convincing, noninvasive methods for tracking disease progression both in animal models and in human clinical 22 trials. Here, we unveil a new translational platform for tracking disease progression in an animal model of a 23 pediatric neurodegenerative disorder, CLN6-Batten disease. Instead of looking at a handful of parameters or a single 24 "needle in a haystack", we embrace the idea that disease progression, in mice and patients alike, is a diverse 25 phenomenon best characterized by a combination of relevant biomarkers. Thus, we employed a multi-modal 26 quantitative approach where 144 parameters were longitudinally monitored to allow for individual variability. We 27 use a range of noninvasive neuroimaging modalities and kinematic gait analysis, all methods that parallel those 28 commonly used in the clinic, followed by a powerful statistical platform to identify key progressive anatomical and 29 metabolic changes that correlate strongly with the progression of pathological and behavioral deficits. This 30 innovative, highly sensitive platform can be used as a powerful tool for preclinical studies on neurodegenerative 31 diseases, and provides proof-of-principle for use as a potentially translatable tool for clinicians in the future. 32 33 [Main Text: ] 34
Introduction 35
Rare diseases, conditions that affect fewer than 200,000 patients in the U.S. or less than 1 in 2,000 people in the EU (1), 36 represent a particular challenge for medical diagnosis as clinical features are often complex and enigmatic. While very few rare 37 diseases have effective treatments, resulting from the limited information that is typically available for many of these conditions, 38 access to improved animal models and state-of-the art medical diagnostic capabilities are helping to accelerate the number of clinical 39 trials and treatments available to patients. Due to their rarity, access to patients is particularly limited, so researchers and clinicians 40 must rely on comprehensive natural history studies that provide a snapshot of where a typical patient would exist in time. Moreover, 41 because many of these diseases are pediatric and ultimately fatal, the Rare Diseases Act of 2002 made it possible to accelerate the 42 clinical trial design process, with one concession being that the trial need not include untreated controls, thus making the natural 43 history data even more essential. Although much attention has been focused on collecting this information, much of what is captured 44
can be subjective and qualitative. Thus, quantitative biomarkers that can be monitored longitudinally and are minimally invasive are 45 greatly needed in order to monitor treatment responses in both preclinical animal models and human clinical trials. Translational 46 utilization of animal models of human disease benefits greatly from relevant phenotypic characterization. Unfortunately, the 47 techniques most commonly used in animal models often suffer from a lack of translatability. Behavioral assays for mice most often 48 focus on murine-relevant behaviors that are not necessarily applicable to the clinic. Similarly, mouse pathology is typically focused on 49 invasive post-mortem analysis of tissues, processes that are not practiced in human patients. This lack of translatability renders many 50 preclinical phenotypic characterizations difficult to translate to the clinic. 51
Comprehensive noninvasive biomarker panels are not available for many neurodegenerative disorders, and these are of 52 special interest for pediatric disorders, as determining disease progression early on is critical to identifying proper clinical 53
interventions and monitoring responses to potential corrective therapies. Batten disease (i.e., neuronal ceroid lipofuscinoses), a family 54 of lysosomal storage disorders resulting from mutations in one of 13 genes, collectively represents the most common 55 neurodegenerative disease in children (2, 3) . Although the functions of many of these genes are unknown, much work in the past 56 decade has been dedicated to developing and testing therapies. With the recent advancements in research tools, including high-57
throughput and high-content screening methods, the Batten disease scientific community has been progressing toward potential 58 therapies at an unprecedented pace, and as a result, treatments are moving from the preclinical phase to clinical trials more quickly and 59 efficiently than ever before. Also, with such heterogeneous disease states, resulting from different mutations that lead to more 60 aggressive or protracted forms of the disease, clinical research teams are forming large, international collaborations to ensure that 61 comprehensive natural history studies are completed and in place as a resource for all clinical trials. These interdisciplinary groups 62 have paved the way for these natural history studies, led by the DEM-CHILD NCL Patient Database Consortium and the University of 63
Rochester Batten Center (4, 5). Additionally, these groups have developed clinical rating scales to assess cognitive, motor, and 64 behavioral function of patients with Batten disease (6-8). With a growing number of clinical trials for Batten disease therapies, there is 65 an increasing need for noninvasive, clinically-relevant biomarkers to track therapeutic efficacy. 66
To address these needs, we used a mouse model of CLN6 Batten disease to perform an exhaustive multi-factorial 67 characterization of biomarkers, moving away from mouse behavioral assays to clinical outcomes that are congruent to those used in 68 human patients. CLN6 disease is caused by autosomal recessive mutations in CLN6, which results in the reduction or complete 69 absence of the CLN6 protein. This disease is characterized by the accumulation of autofluorescent storage material in lysosomes, 70 progressive neurodegeneration throughout cortex and thalamus, as well as massive gliosis throughout the central nervous system 71 (CNS). Patients often present with language deficits, cognitive impairment and progressive motor decline. As the disease progresses, 72 patients lose vision, develop seizures and ultimately succumb to the disease around 10-12 years of life. The spontaneously occurring 73 Cln6 nclf mouse model of CLN6 disease has been shown to faithfully recapitulate many of the hallmarks of the human disease both 74 behaviorally and pathologically (9, 10), but noninvasive, clinically relevant assays have not yet been employed to characterize 75
longitudinal changes in this model. Various scientists, our lab included, have performed a very comprehensive pathological 76 assessment of Batten disease rodent and large animal models to reveal how different brain regions change over time, however, these 77 experiments were all conducted on post-mortem brain samples (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . These studies have shown that brain pathology is present 78 months before any noted behavioral changes, similar to what has been noted in human patients. Thus, cellular changes and 79 degeneration are occurring in the the brain long before one notices any behavior or cognitive changes, so developing more sensitive 80 tools for detecting disease states prior to the onset of behavioral symptoms would be of immense value in the clinic. Our previous 81 work, as well as the work of others, has largely been focused on finding a single biomarker -the elusive "needle in a haystack" -82 associated with Batten disease and its progression (21-24), but this approach has failed to yield any reliable metrics. 83
In this study, rather than focusing on one or a few metrics, we used multiple imaging modalities as well as a comprehensive 84 gait assessment to track hundreds of parameters over time, and performed a combinatorial analysis to identify a biomarker signature 85 for CLN6-disease. Cohorts of wild type and Cln6 nclf mice of both sexes were monitored longitudinally using noninvasive imaging, 86
including T2-weighted magnetic resonance imaging (T2-MRI), diffusion tensor MRI (DTI), 1 H magnetic resonance spectroscopy 87 (MRS), and positron emission tomography (PET) was performed periodically between 3-12 months of age while kinematic gait 88 analysis (KGA), which captures a large number of metrics describing gait, was assayed from 6-12 months of age. Variations of all of 89 these techniques are widely used in the clinic and have shown correlations between mouse models and human subjects (25, 26). Once 90
we had characterized these parameters in the CLN6 disease mouse model, we used a recently developed form of principal component 91 analysis (PCA), contrastive PCA (cPCA), to cluster the four imaging modalities and gait analysis in order to derive new variables that 92 best capture and define the progressive nature of the disease. Together, this approach provides a robust and translatable platform for 93 longitudinal monitoring of disease progression that can have profound utility, not only for Batten disease, but in a variety of animal 94 models of rare neuropediatric diseases. 95
96
Results 97
Progressive changes in brain volume and anatomy in a model of CLN6 disease. 98
The selective vulnerability of various populations of neurons is a key feature of many neurodegenerative diseases, including 99
Batten disease (27, 28) . Prior studies have demonstrated that thinning of select anatomical regions and different cortical layers is 100 present in Cln6 nclf mice (9, 12, 14, 19) , however, all of these measurements are based on invasive, histopathological analysis of post-101 mortem tissues. To identify progressive changes in brain architecture, we examined cohorts of mice longitudinally up to one year of 102 age with T2 weighted magnetic resonance (T2-MRI) and diffusion tensor imaging (DTI). 103 Whole brain volume steadily decreased over time in Cln6 nclf mice, with lower volume noted at 6, 9 and 12 months of age with 104 clear differences in unique brain regions ( Fig. 1) . Progressive cortical atrophy began at 9 months and was profound at 12 months, 105
where cortical volume was reduced in size by ~14%. Milder atrophy was also observed in the cerebellum at 12 months, culminating in 106 a ~9% reduction in volume. Interestingly, there was a slight but significant increase in whole brain volume at 3 months of age (~1%). 107
Historically, scientists have focused on one sex or mixed sexes for behavioral and pathological changes rather than analyzing them 108
individually. Here we separated and tracked individual sexes, providing an innovative way of monitoring these animals over time and 109 strengthening the translational utility. Sex differences were also evident, with the increase in whole brain volume at 3 months seen 110 solely in male Cln6 nclf mice, but decreasing in both sexes beginning at 6 months of age ( Fig. S1 , Table S1 ). Cortical atrophy also 111 appeared earlier (at 9 months) in females than in males (at 12 months). In human patients and mouse models of neurodegenerative 112 diseases, such profound cortical atrophy is typically accompanied by an increase in lateral ventricle volume (29) . Surprisingly, we did 113 not detect such changes in the Cln6 nclf mice. Still, these results suggest progressive neurodegeneration results in multiple changes in 114 brain structure volumes over the time course of the disease. 115
To determine whether reductions in grey matter volume were accompanied by corresponding changes in white matter 116 perturbations, we performed DTI to measure fractional anisotropy (FA) of several major CNS axon tracts. FA as measured by DTI 117 reflects the level of preferred directionality of the diffusion of water molecules. Thus, higher FA values can reflect greater numbers, 118
packing, or diameters of axons, lower variability in axon orientation, or more dense myelination (30). There were varying changes in 119
FA of the forceps minor of the corpus callosum (fmi) over the time points monitored, and a consistent decrease in FA in the anterior 120 portion of the anterior commissure (aca) beginning at 6 months of age ( Fig. 2) . Additionally, there were several regions with a 121 decrease in FA at 12 months of age, correlating with the progressive and profound atrophy occurring at this time point. Within 122 individual sexes, the FA of the fmi was increased in a male specific manner at 6 and 9 months of age ( Fig. S2) . Female Cln6 nclf mice 123 showed a decreased in FA in the splenium of the corpus callosum (scc) at 6 months of age, prior to their male counterparts, while both 124 sexes began showing a decrease in FA in the aca beginning at 6 months of age ( Fig. S2 , Table S2 ). By 12 months of age, both sexes 125 showed decreased FA in several white matter areas. These results demonstrate that progressive white matter defects are also prevalent 126
in Cln6 nclf mice, with unique sex specific perturbations in various white matter regions. 127
Alterations in brain metabolism, metabolites, and markers of brain inflammation associated with CLN6 disease. 128
Abnormalities in brain metabolism in the form of decreases in glucose uptake and increases in various markers of 129 neuroinflammation is a common signature of a number of neurodegenerative disorders (31, 32). To explore whether such changes are 130 present in the CLN6-Batten disease mouse model, we performed 1 H magnetic resonance spectroscopy (MRS) and positron emission 131 tomography (PET) imaging. MRS was first used to examine longitudinal changes in various brain metabolites in the frontal cortex. 132
While we observed subtle changes in a variety of metabolites at various time points, the most significant changes were observed for 133 glutamine (GLN), N-acetylaspartate (NAA), and NAA + N-acetylaspartylglutamic acid (NAA+NAAG) ( Table 1) . GLN levels 134 steadily increased in Cln6 nclf mice over time, reaching significantly elevated levels at 12 months of age in both sexes ( Table 1) . NAA 135 and NAA+NAAG levels steadily decreased over time, reaching significantly lower levels at 9 and 12 months of age in both sexes. 136
Additionally, taurine (TAU) was reduced at 3 -9 months, more prominently in male mice, and creatine (Cr) + phospho-creatine (PCr) 137 reduced at 3 months in female mice, though these differences resolved over time. These results suggest that alterations in glutamate-138 glutamine cycling and excitatory signaling may be a prominent feature of this disease model, mirroring what has been found in other 139 studies(33) . Furthermore, NAA decreases we observed mirror those seen in human patients with a number of neurodegenerative 140 disorders including Batten disease (34-36), suggesting that this may be a useful marker for monitoring neurodegeneration in Cln6 nclf 141 mice. 142
To explore potential changes in brain metabolism (i.e. brain glucose utilization), we used PET to monitor uptake of 143 fluorodeoxyglucose ( 18 F, FDG), a PET-detectable proxy for glucose. At 12 months, where we observed the most severe alterations in 144 brain anatomy, we found that FDG standardized uptake values (SUV) were significantly compromised in all regions examined in male 145
Cln6 nclf mice and in many regions in female Cln6 nclf mice ( Table 2) . We also utilized PET to measure the uptake of 18 F-FEPPA. This 146 ligand binds the translocator protein (TSPO), which is upregulated in microglia in response to neuroinflammation, one of the earliest 147 reported pathological changes in Batten disease mouse models (37). Interestingly, at 13 months of age, uptake was reduced in male 148 mice in the basal forebrain and septum (BFS), cortex, and olfactory bulb while increased uptake was found in females in the central 149 gray matter, superior colliculi, and thalamus (Table S3 ). It must be noted, however, that we observed significantly decreased body 150 weights in male and female Cln6 nclf mice at this time point ( Fig. S3 ). Since SUV is negatively correlated with body weight, this 151 complicates any comparison of SUV values between groups. These results, obtained at the advanced stage of 13 months of age, 152
suggest that finding significant differences in 18 F-FEPPA uptake at earlier time points may be even more challenging. Taken together, 153 the differences we observed could be indicative of alterations in glucose uptake, brain perfusion, neuronal metabolism, and 154 inflammatory status. 155
Kinematic Gait Analysis identifies novel motor disturbances in Cln6 nclf mice. 156
The profound anatomical and metabolic abnormalities we observed in Cln6 nclf mice would be expected to lead to behavioral 157 disturbances. While motor coordination deficits have been identified in Cln6 nclf mice using crude measures such as rotarod 158 performance (9, 38), an exhaustive analysis of gait parameters that have good human correlates in the clinic has not been conducted. 159 We used kinematic gait analysis (KGA) to examine 97 gait parameters longitudinally in the Cln6 mutant mice ( Table S4 , Fig. S4-S9) . 160 This included a detailed analysis of gait cycle, body and head orientation and positioning, and multiple fore and hind limb parameters. 161
Additionally, we used a PCA based approach to calculate overall gait scores. 162
Many individual parameters varied between genotypes and time points, but several predominant gait features defined the 163
Cln6 nclf gait. Cln6 nclf mice ambulated with slower overall speed, decreased durations of diagonal gait mode (trotting), increased 164 durations of double support, slower overall speed, lower hind body posture reflected in lower tail base, hip and iliac crest heights and 165 decreased knee and ankle heights, and elevated tow clearance in both fore and hind limbs ( Fig. S4) . Different gait features, which are 166 manifested in sets of highly correlating parameters, can be identified using principal component analysis [PCA; (39)]. PCA is a 167 commonly used technique to reduce the dimensionality of multivariate data sets (40, 41), or more specifically, to determine a few 168 linear combinations of the original variables that can be used to summarize the data set while retaining as much information as 169 possible. Moreover, the use of PCA also enables the inspection and identification of the mutual correlations between the original 170 kinematic parameters. PCA based calculation of overall gait scores revealed profound and progressive changes in Cln6 nclf mice ( Fig.  171 3). The overall score is a weighted average of the gait variables using weights from the discriminant vectors, which emphasizes which 172 kinematic parameters are contributing to the overall score ( Fig. 3B) . When analyzing pooled sexes, Cln6 nclf gait scores were 173 significantly different from controls at all time points, culminating in an approximately 12-fold increase at 12 months of age. When 174 analyzing sexes individually, individual sex score in males increased significantly beginning at 6 months of age. In females, the 175 differences was significant only at 12 months of age. Additionally, there was a significant genotype by age interaction in gait scores, 176 supporting differences in gait over time across the two genotypes ( Fig. 3A) . These results demonstrate that Cln6 mutant mice have 177 profound, progressive gait disturbances, mirroring phenotypes that have been described in human CLN6 disease patients (42, 43). 178
Contrastive PCA identifies the core progressive symptomatology in Cln6 nclf mice. 179
Where other studies or natural history studies have fallen short is that they try to look at each individual parameter in 180 isolation rather than looking at the system as a whole. We performed contrastive PCA (cPCA) in an effort to holistically capture the 181 progressive changes present in Cln6 nclf mice. Our phenotypic analysis identified a number of novel anatomical, metabolic, and 182 behavioral phenotypes associated to the Cln6 mutant animals. This large volume of data presented an important question: Is there a 183 core set of phenotypes that strongly correlate with one another and best describe the progressive nature of the Cln6 nclf disease course? 184
Identifying such a set of phenotypes would be of great utility in utilizing this model for not only preclinical testing of novel therapies 185 but could have profound clinical value. So instead of looking for 'a single needle in a haystack,' we analyzed 'the whole haystack' 186 using statistical methods capable of reducing the data without losing any information. 187
To perform this analysis, we used a recently developed statistical technique, contrastive PCA (cPCA) (44). This procedure 188 identifies a low dimensional structure that is enriched in one genotype over another, thus calculating cPC scores that accentuate 189 differences between genotypes. Our analysis included MRI volumetry from 6 brain regions, DTI from 9 white matter regions, MRS 190 for 19 metabolites in the PFC, FDG-PET from 15 brain regions, and KGA for 97 parameters, longitudinally from both genotypes of 191 mice. First, we calculated 1st level principal components (PCs), three for each modality. This reduced the original 144 variables 192 yielding 15 unique variables (PCs), many of which highlighted progressive changes in Cln6 nclf mice (Fig. 4) . 193
Next, we used cPCA to calculate 2nd level cPC scores based on the 1st level PCs (Fig. 5) .The top cPC score, cPC1, included 194 contributions primarily from MRI, FDG-PET, DTI, and KGA, demonstrating that gait performance was associated with anatomical 195 and metabolic changes in various brain regions ( Fig. 5A) . cPC1 proved to be very effective at characterizing phenotypic progression 196
in Cln6 nclf mice (Fig. 5B) . The top 5 features (i.e., the five 1st level PCs with highest contribution) in the cPC1 were: 1) MRI PC1 197
(overall brain volume), 2) KGA PC1 (overall speed + diagonal cadence + overall hip height), 3) FDG PC3 (increase in striatum, 198 central grey matter, and basal forebrain associated with decrease in cerebellum and olfactory bulb.), 4) DTI PC1 (overall level), and 5) 199 DTI PC2 (increase in the body of the corpus callosum and splenium of the corpus callosum, decrease in anterior commissure, internal 200 capsule and cerebral peduncle) . Taken together, the decreased cPC1 score in Cln6 mutant mice can be interpreted as decrease in 201 structural brain volume (MRI PC1) associated with decrease in overall mobility (KGA PC1), and metabolic changes (FDG PC3), and 202 reductions in overall (DTI PC1) and local (DTI PC2) anisotrophy. Remarkably, the genotype difference was significant at each of the 203 time points examined for pooled sexes, as well as each sex separately. The second cPC, cPC2, highlighted a much wider variability in 204
Cln6 nclf mice at all time points. The variation in cPC2 is mostly explained by difference between sexes within Cln6 mutant animals. 205
There was a significant difference between Cln6 nclf male versus Cln6 nclf female at all time points. The variation in cPC2 is mostly 206 explained with MRI PC2 (hippocampus (↑), cerebellum/lateral ventricles (↓)) and MRI PC3 (cerebellum (↓), lateral ventricles (↑)) 207 ( Fig. 5A) . However, partially due to this variability, differences between genotypes were mostly insignificant ( Fig. 5B) . Still, cPC1 208 provides a powerful summary of the Cln6 nclf phenotype starting early in disease, and could be the basis for highly sensitive assays for 209 future therapeutic testing. Thus, the data from this comprehensive analysis could be used for generating a final disease score, given the 210 longitudinal differences between genotypes. Such a score could in turn be used to determine efficacy of potential treatments provides an innovative way of monitoring these animals over time, strengthening the translational utility. Our findings reinforce that 223 the Cln6 nclf model recapitulates many aspects of the human disease course, including the progressive nature, of CLN6 disease. We 224
show that Cln6 nclf mice have profound and progressive changes in brain anatomy and metabolism, and that these changes correlate 225 strongly with abnormalities in gait parameters. cPC1, which encapsulates the changes that appeared most consistently and with the 226 greatest magnitude, shows very large and increasing differences between wild type and Cln6 nclf mice from 6-12 months of age. In 227 addition to providing insights into the pathological manifestations of Cln6 deficiency, this work suggests a number of clinical 228 assessments that may be most useful in assessing CLN6 patients. Although our genetically identical mice differ in many important 229 ways from a more heterogeneous population of human patients, the beauty of this system is that it isn't reliant on one metric to 230 produce the score of disease state, and can still detect progressive changes in the presence of between-individual variance. 231
In Batten disease patients, general brain structure changes include cerebral and cerebellar atrophy, callosal thinning, enlarged 232 ventricular space, white matter maturation, and thalamic density, which may appear abnormal before any clinical symptoms appear 233 (29, 53, (55) (56) (57) (58) (59) (60) (61) (62) (63) . The functional imaging modalities employed here revealed significant changes in the diseased mice that also correlate with 243 similar changes reported for Batten disease patients. The Cln6 nclf mice display generalized whole brain atrophy starting at 6 months of 244 age that rapidly progresses, and a reduction in brain metabolites and metabolism as measured by MRI, MRS and FDG-PET, 245
respectively. Region-specific volumetry changes included decreased volume of the cortex and cerebellum. Additionally, there was an 246 opposite trend between male and female diseased mice for lateral ventricle volume, with males showing an increase in ventricular 247 volume at 3 months that was stabilized through 12 months of age, while females showed a steady decrease in ventricular volume over 248 time. These results may be in part due the general decrease in brain volume for both sexes. MRS identified a severe reduction in NAA 249 at 9 -12 months for both males and females. FDG-PET revealed highly reduced glucose metabolism in all brain regions at 12 months 250 of age. Diffusion tensor MRI and fractional anisotropy showed that brain changes in Cln6 nclf mice involve not only grey matter, but 251 white matter as well. Contrary to many neurodegenerative diseases where corpus callosum changes are often pronounced, deeper 252
white matter structures such as anterior commissure, external and internal capsule seem to be primarily affected in CLN6 nclf mice 253 although corpus callosum changes become evident with disease progression. Decrease of FA is normally attributed to e.g. 254 demyelination, axonal loss/disruption or incoherence due to pathological processes. Unfortunately, supporting NCL related histology-255 verified DTI research, both clinical and pre-clinical, is still largely lacking. Our data takes important steps in providing observations 256 from animal models of NCL that can be utilized to justify the use of DTI more often in a neuroradiological assessment of Batten 257 disease. 258
Although motor coordination deficits have been identified in Cln6 nclf mice using behavioral tests such as rotarod performance 259 (9, 38), traditionally, there have been significant inter-and intra-lab variability in animal behavior testing. Variation in behavior results 260 have depended on genetic background of the mouse model, genetic drift, breeding strategies, geographical location of testing facility, 261 variability in behavior protocols implemented, gender of the animal handler, animal diet, and water quality (75, 76). As for differences 262 in behavior testing protocols, different labs implement various training time and number of repeated measures. Fine kinematic gait 263 analysis conducted on 97 unique measurements identified unique movement scores among the Cln6 nclf mice. The overall gait score is 264 based on differences between the wild type and Cln6 nclf groups in all the PC scores. Ultimately, the overall kinematic effects of a 265 pharmacological agent may be seen in a highly sensitive manner with a wide therapeutic window, which suggests that this tool will be 266 of great value for further preclinical and translational studies in various neurodegenerative disease. 267
Our results demonstrate the translational power of an exhaustive, multi-factorial characterization of biomarkers in the Cln6 nclf 268 mouse model of CLN6 disease. Our characterization suggests which clinical tools may be most useful in monitoring patients, and also 269 provides a highly sensitive platform for testing therapies in mice. We focused on two main categories of tools which have direct 270 correlates in the clinic: kinematic gait analysis (KGA) and noninvasive neuroimaging. KGA monitors ambulating mice, capturing a 271 large number of metrics that together describe deviations from normal gait. This method is widely employed in the clinic to 272 objectively describe gait abnormalities in patients. While there are large differences in ambulation mode between bipedal humans and 273 quadrupedal mice, recent developments have demonstrated correlations between parameters of human and mouse gait, and the 274 translational utility of gait analysis in mouse models (25). Similarly, in terms of noninvasive brain imaging, there are many anatomical 275 similarities between the human and murine brain, and studies have shown that noninvasive imaging often detects similar changes in 276 human patients and mouse models of neurodegenerative disease (26). 277 Furthermore, many researchers have focused on single blood-, saliva-, and cerebrospinal fluid-based biomarkers in mice and 278 large animal models of Batten disease (21-23, 77-80). These focused studies have led us to conclude that no singular target will 279 provide a reliable biomarker of Batten disease. Additionally, one particularly important study analyzed autopsy brains and 280 cerebrospinal fluid (CSF) from deceased Batten disease patients and identified numerous significant changes of potential biomarkers 281 of disease (81). However, this study was conducted on post-mortem brain samples and CSF, which would represent samples that are 282 either impossible to analyze in living patients or invasively acquired. We sought to go beyond simply identifying a single biomarker or 283 group of phenotypes that are present in this mouse model, and to provide a more useful characterization that also identifies which 284 phenotypes correlate most closely with one another, and which phenotypes best demonstrate the progressive nature of the disease. To 285 accomplish this goal, we used cPCA, which is highly effective for identifying the parameters that best define the differences between 286
groups. This analysis is intended to identify cPCs that amplify the differences between healthy and disease subjects, thus increasing 287 the sensitivity to detect changes, positive or negative, in disease progression. Such a metric could have great power for identifying 288 potentially useful therapies in preclinical studies in mice, large animal models, or for quantifying progression or therapeutic benefit in 289 patients, and removes the barrier of looking for a single biomarker of disease by combining multiple biomarkers into one clinical score 290 of disease state/progression. 291
The strength and novelty of this study stems from utilizing multiple non-invasive functional imaging modalities to 292 longitudinally track and compare wild type and diseased animals over time, and combining the noninvasive imaging, including T2-293 MRI, DT, MRS, and PET, with KGA in a cPCA to generate a disease score. This score identifies diseased animals and provides a 294 robust and translatable platform for long term monitoring of animal models of disease that can also be applied to large animal models 295 of neurodevelopmental and neurodegenerative diseases as well as clinical patients. The platform we have developed will be widely 296 applicable to the study of a variety of animal models of neurodegenerative disease. In addition to identifying novel phenotypes of 297 these disorders, this combination of neuroimaging, behavior, and statistical analysis should enable the identification of cPCA-based 298 phenotypes that accentuate progressive changes, greatly enhancing the power of these models for preclinical studies. Furthermore, the 299 translational nature of the techniques this platform utilizes may provide important insights for clinicians regarding which noninvasive 300
imaging and behavioral modalities may be most useful in the diagnosis and ongoing assessment of patients with neurodegenerative 301 diseases. Establishing these parameters for patients with neurodegenerative diseases is imperative for future drug screening and utility 302 in human clinical trials. For CLN6 disease patients currently enrolled in the phase I/II clinical trial (ClinicalTrials.gov Identifier: 303 NCT02725580) (82), there is currently no way to conclusively monitor responses to these treatments over time. Having these 304 capabilities in place would allow for quantitative analysis of patient responses. Additionally, in the future these metrics may be 305 combined with existing data from blood-and CSF-based biomarkers to develop a comprehensive panel of noninvasive biomarkers for 306 many neurodegenerative diseases. 307 308
Materials and Methods 309

Study Design 310
Neuroimaging, gait analysis, and principal component analyses were conducted on aged-matched wildtype and Cln6 mutant 311 mice (description of animals in Ethics Statement/Animals) to determine a longitudinal biomarker scoring system in a preclinical 312 model of neuropediatric disease. We hypothesized that by looking at various non-invasive disease markers as a system, rather than 313 individually, we could provide a highly sensitive tool that may be translatable to the clinic. Sample size, endpoints, and rules for 314 stopping data collection were determined based on our previously published studies on this model (83). No outliers were removed 315 from any data sets. All animal experiments were performed as specified in the license authorized by the national Animal Experiment 316
Board of Finland and according to the National Institutes of Health (Bethesda, MD, USA) guidelines for the care and use of laboratory 317
animals. Experiments were conducted in an AAALAC accredited laboratory. Animals' care was in accordance with institutional 318 guidelines. 3-13 month, male and female wild type (WT) and homozygous Cln6-mutant mice (Cln6 nclf ; JAX stock #003605) on 319 C57BL/6J backgrounds were utilized for all studies, were housed under identical conditions, and all experimenters were blinded to 320 genotype. 321
Magnetic Resonance Imaging and Spectroscopy 322
MRI experiments were performed using a horizontal 11.7T magnet with a bore size of 160 mm, equipped with a gradient set 323 capable of maximum gradient strength of 750 mT/m and interfaced to a Bruker Avance III console (Bruker Biospin GmbH, Ettlingen, 324
Germany). A volume coil (Bruker Biospin GmbH, Ettlingen, Germany) was used for transmission and a surface phased array coil for 325 receiving (Rapid Biomedical GmbH, Rimpar, Germany). Mice were anesthetized using isoflurane, fixed to a head holder and 326 positioned in the magnet bore in a standard orientation relative to gradient coils. Temperature of the animals were monitored and 327 maintained between 36-37°C throughout the experiments. To avoid prolonged anesthesia/study day, MR experiments were performed 328 in two separate scanning sessions; 1) MRI volumetry and localized 1H-MR spectroscopy from frontal cortex (total duration appr. 45 329 minutes) and 2) diffusion tensor imaging (DTI, total duration appr. 1 hour). 330
Structural MRI was performed with a standard Turbo-RARE sequence with TEeff of 34 ms (RARE factor of 8), TR of 3150 331 ms and 8 averages. Thirty-one 0.45 mm slices were collected with field-of-view of 20x20 mm 2 and 256x256 matrix (78 microns in-332 plane resolution). Region of interest analysis was performed in MATLAB (Mathworks Inc., Natick, MA, USA) environment observer 333 blinded for study groups. Whole brain, cortex, striatum, hippocampus, lateral ventricle and cerebellar volumes were analyzed. 334
For the acquisition of proton MRS data, frontal cortex voxel (2.2x1.6x1.8 mm3, 6.3 μl localized volume) was selected based 335 on structural MR images described above. Automatic 3D gradient echo shimming algorithm was used to adjust B0 homogeneity in the 336 voxel. The water signal was suppressed using variable power RF pulses with optimized relaxation delays (VAPOR) to obtain B1 and 337 T1 insensitivity. A PRESS sequence (TE = 10 ms) combined with outer volume suppression (OVS) was used for the pre-localization. 338
Data were collected by averaging 512 excitations (frequency corrected for each FID) with TR of 2 s, number of points 2048 and 339 spectral width of 5 kHz. Excitation frequency was shifted -2 ppm, to minimize the chemical shift phenomenon within the selected 340
voxel. In addition, a reference spectrum without water suppression (NT=8) was collected from the identical voxel using the same 341 acquisition parameters. Peak areas for resolved metabolites were analyzed using LCModel (Stephen Provencher Inc., Oakville, 342
Canada) using >CRLB 20% as exclusion criterion for individual metabolites within analyzed spectrum. 343
Diffusion tensor MRI (DTI) was performed using 4-segment EPI sequence with 30 diffusion directions (TE/TR =23.5/4000 344 ms, b-values 0 and 970 s/mm2). Field-of-view of 12.80 x 10.24 mm2 (with saturation slice) was used with matrix of 160 x 128, 345
resulting 80 microns in-plane resolution. Fifteen 0.6 mm slices were acquired with 6 averages. Preprocessing of DTI-data consisted 346 eddy-current correction and brain masking. Diffusion tensor was calculated using FSL (https://fsl.fmrib.ox.ac.uk/fsl/) and resulting 347 fractional anisotropy maps were processed with manual ROI-analysis in the MATLAB environment (Mathworks Inc.) for the 348 following anatomical structures; forceps minor of the corpus callosum (fmi), genu of corpus callosum (gcc); body of corpus callosum 349 (bcc); splenium of corpus callosum (scc); external capsule (ec); anterior commissure anterior part (aca); internal capsule (ic); optic 350 tract (opt); cerebral peduncle (cp). 351
Longitudinal 18 F-FDG and 18 F-FEPPA PET Imaging 352
The Cln6 nclf and wild type mice were longitudinally PET scanned at the age of 4, 6, 9 and 12 months. After an overnight 353 fasting, to standardize blood glucose levels, the mice were injected intravenously with a 150 µl bolus of 18 F-FDG in sterile saline, 14.0 354 ± 1.5 MBq. The mice were anesthetized with isoflurane 20 minutes after the injection and positioned into small animal PET/CT 355 (BioPET/CT, BioScan, USA). Three mice were scanned simultaneously in list mode for 25 minutes, 30 minutes post the 18 F-FDG 356 injection. PET scan was followed by CT scan for anatomical orientation and CT-based attenuation map for image reconstruction. The 357 sinograms were reconstructed with 3D-OSEM, 1 iteration and 25 subsets, with attenuation correction. Image analysis was performed 358
with PMOD software (PMOD Technologies, Switzerland, v.3.7). The PET images were co-registered with mouse brain MRI template 359 and standardized uptake values (SUVs) were calculated on different brain regions. 360
At the age of 13 months the Cln6 nclf and wild type mice were anesthetized with isoflurane, cannulated into lateral tail vein and 361 positioned into small animal PET/CT (BioPET/CT, BioScan, USA). Dynamic 90.5 minute PET scan was started and 150 µl of [ 18 F] 362 FEPPA, 11.4 ± 1.0 MBq, was injected intravenously 30 seconds after the start of the scan. PET scan was followed by CT scan for 363 anatomical orientation and CT-based attenuation map for image reconstruction. The sinograms were reconstructed with 3D-OSEM, 1 364 iteration and 25 subsets, with attenuation correction. Image analysis was performed with PMOD software (PMOD Technologies, 365
Switzerland, v.3.7). The PET images were co-registered with mouse brain MRI template and standardized uptake values (SUVs) were 366 calculated on different brain regions from last 30 minutes of the PET scan. 367
Fine motor kinematic analysis 368
Mice were subjected to kinematic gait analysis test at 6, 9, and 12 months of age, using a Motorater apparatus (TSE-Systems 369
GmbH, Bad Homburg, Germany) designed for the assessment of fine motor skills in rodents. The equipment consists of a brightly 370 illuminated Plexiglas corridor (153 x 5 x 10 cm) under which is situated a high-speed camera. Prior to the test, the mice were shaved 371 under light isoflurane anesthesia, and the essential body points, such as joints and tail, were marked for tracking. The gait performance 372
data was captured using a camera operated 300 frames per second, imaging the gait simultaneously from three different views 373 (underside and both sides). The movement was analyzed from the three views, first using the Simi Motion software (Simi Reality  374 Motion Systems GmbH, Unterschleissheim, Germany). Approximately 5-6 complete strides were analyzed from each mouse. Only 375 strides with continuous ambulatory movement were included in the data. The raw kinematic data thus comprised of the movements of 376 24 different body points in coordinates related to the ground. Different gait patterns and movements were analyzed using a custom 377 made automated analysis software, resulting 97 distinctive kinematic gait parameters(84) ( Fig. S7-S12 ) such as: general gait pattern 378 parameters (e.g., stride time and stride speed, step width, stance time and swing time during a stride, interlimb coordination, etc.), 379 body posture and balance parameters (e.g., toe clearance, iliac crest height, hip height, hind limb pro-, and retraction, tail position, tail 380 movements), and fine motor skills (e.g. swing speed during a stride, jerk metric during swing phase, angle ranges and deviations of 381 distinct joints, vertical and horizontal head movements). PC is discarded, and so on for the rest of the PCs. The total number of PCs was selected using Kaiser's rule, i.e., only those PCs were 387 retained which explain more (variance) than one normalized original variable. The eigenvectors also reveal information about the 388 internal structure of the data, i.e., mutually correlated parameters. Each PC score is emphasized by different combination of mutually 389 correlated original variables. So, each PC is a linear combination of original variables, such that some variables are emphasized in one 390
PC and some other variables in another. Variables which are emphasized in a PC are mutually correlated. On the other hand, the PCs 391 themselves are totally uncorrelated. 392
The Overall Gait Score is based on differences between the wild type and the Cln6 nclf groups in all the PC scores. Thus, the 393 purpose of that score is to identify a combination of original variables, a "fingerprint", which characterizes the disease model in the 394 best possible way and differentiates the two groups. After the "fingerprint", or discriminant direction vector, has been constructed, the 395 overall gait analysis scores are obtained by projecting the (normalized) parameter data of each individual mouse onto the discriminant 396 direction vector. The average wild type group individual has always score equal to zero, and roughly half of the controls have always 397 negative score, reflecting that their overall gait performance is in the opposite direction than the performance of the disease model 398 phenotype. Moreover, the average disease model phenotype has always a positive score value, and the magnitude of that value 399 corresponds to magnitude of phenotype specific deviations in an overall gait pattern. 400
The cPCA is based on PCA of two datasets, X and Y, where X (target) may consist of data of different genotypes, ages, 401 treatments and sexes, and Y (background) consists of control group data, not including variation due to genotype or disease model. 402
The aim in cPCA is to create a subset combination of original parameters, which simultaneously 1) maximizes variance in X 403 (interesting and "universal" features) and 2) minimizes variance in Y ("universal" features only). In other words, the cPCA is used to 404 discover the combination of those interesting variables, which all together add contrast between the background and the target, i.e., 405 genotype specific variables. 406
Statistical Analysis 407
Individual tests were run in Graphpad Prism (Ver 7.04). In general, an ordinary two-way ANOVA was used at each time 408 point, using genotype and brain region/ Table S3 : FEPPA-PET: 18 F-FEPPA standard uptake values 429 and sexes separately (bottom). The first component, most emphasized by MRI PC1, KGA PC1, FDG PC1 and DTI PC1 and 2, demonstrate progressively increasing phenotype difference (*) in both sexes. The cPC2, consisting mostly of MRI PC1 and 2 but also DTI PC3 and FDG PC3, reveals sex difference (#)in Cln6 mice at all ages. n = 6 for WT (3 male, 3 female), n = 7 for Cln6 nclf (4 male, 3 female). Statistical significances: unpaired t-test of estimated mean differences *p < 0.05, **p < 0.01, ***p < 0.001
